

|  |  |
| --- | --- |
| **Examination question paper:** | **May 2024** |

|  |  |
| --- | --- |
| **Module code:**  **Component number:** | **BM7048**  **002** |
| **Module title:** | **Cancer Immunotherapy** |
| **Module leader:** | **Prof. Jameel M. Inal** |

|  |  |
| --- | --- |
| **Date:** | **May 2024** |
| **Duration:** | **1 Hour 30 Minutes** |

|  |  |
| --- | --- |
| **Exam type:** | **Seen, Closed** |
| **Materials supplied:** | **None** |
| **Materials permitted:** | **None** |
| **Warning:** | **Candidates are warned that possession of unauthorised materials in an examination is a serious assessment offence.** |

|  |  |
| --- | --- |
| **Instructions to candidates:** | **Candidates will be required to answer all THREE questions** |
|  |  |
|  |  |
|  | **Do not turn page over until instructed** |

© London Metropolitan University

**Answer all THREE questions**

**Q1. Discuss the following statement ‘*Vesicle populations derived from tumours mimic the very same immunomodulatory activities that parent tumour cells have*.’**

**20 marks**

**Q2. With respect to DNA vaccination, explain some of the extracellular and intracellular barriers to delivery of DNA and how the use of a ‘nanoparticulate cancer vaccine,’ (so-called nanogel) may constitute a successful delivery system**.

**20 marks**

**Q3. Briefly set the scene for how a tumour controls its surroundings, manipulating infiltrating cells; outline some of the immune effector mechanisms and how re-targeting them may form the basis of cancer immunotherapies.**

**20 marks**